Roivant Sciences Ltd. (NASDAQ:ROIV) saw an upside of 1.29% to close Tuesday at $8.61 after adding $0.11 on the day. The 5-day average trading volume is 2,710,240 shares of the company’s common stock. It has gained $9.59 in the past week and touched a new high 1 time within the past 5 days. An average of 2,811,470 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,324,126.
ROIV’s 1-month performance is 18.76% or $1.60 on its low of $6.65 reached on 01/04/23. The company’s shares have touched a 52-week low of $2.52 and high of $10.00, with the stock’s rally to the 52-week high happening on 01/12/23. YTD, ROIV has achieved 7.76% or $0.62 and has reached a new high 7 times. However, the current price is down -13.90% from the 52-week high price.
ROIV stock investors last saw insider trading activity on Jan 05.Venker Eric (President & COO) most recently sold 24,037 shares at $8.02 per share on Jan 05. This transaction cost the insider $192,777. President & COO, Venker Eric, sold 95,484 shares at a price of $7.32 on Jan 03. Then, on Dec 30, President & COO Venker Eric sold 23,761 shares at a price of $8.00 per share. This transaction amounted to $190,088.
Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 123.50 while the price-to-book (PB) in the most recent quarter is 5.19.
Roivant Sciences Ltd.’s quick ratio for the period ended June 29 was 7.40, with the current ratio over the same period at 7.40. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.32, while the total debt to equity was 0.35.. In terms of profitability, the gross margin trailing 12 months is 85.70%. The firm’s gross profit as reported stood at $46.32 million against revenue of $55.29 million.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 28.5% to -$291.59 million, while revenue of -$331.81 million was -13.79% off the previous quarter. Analysts expected ROIV to announce -$0.32 per share in earnings in its latest quarter, but it posted -$0.48, representing a -50.00% surprise. EBITDA for the quarter stood at more than -$280.77 million. ROIV stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 701.38 million, with total debt at $489.28 million. Shareholders hold equity totaling $725.42 million.
Let’s look briefly at Roivant Sciences Ltd. (ROIV) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 48.58% to suggest the stock is trending Neutral, with historical volatility in this time period at 51.27%.
The stock’s 5-day moving average is $8.79, reflecting a -8.40% or -$0.79 change from its current price. ROIV is currently trading +19.58% above its 20-day SMA, +146.00% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +69.82% and SMA200 by+107.47%.
Stochastic %K and %D was 59.10% and 62.69% and the average true range (ATR) pointed at 0.52. The RSI (14) points at 54.73%, while the 14-day stochastic is at 58.51% with the period’s ATR at 0.52. The stock’s 9-day MACD Oscillator is pointing at -0.58 and -0.44 on the 14-day charts.
In the most recent analyst report for Roivant Sciences Ltd. (NASDAQ: ROIV), JP Morgan launched coverage with an Overweight rating. Analysts offering their rating for ROIV stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ROIV as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 9 have offered a “buy” rating.
What is ROIV’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $10.00 and a high of $19.00, with their median price target at $13.00. Looking at these predictions, the average price target given by analysts is for Roivant Sciences Ltd. (ROIV) stock is $13.13.